Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Pancreatic Ductal Adenocarcinoma (mPDAC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California, San Diego, La Jolla, California, United States
Contact: Study coordinator (Gastrointestinal Research Team) · CancerCTO@health.ucsd.edu · 858-822-5354
Study leads
Gregory P Botta, MD, PhD
Principal Investigator
University of California, San Diego